Patients with hepatocellular carcinoma (HCC) bear a heavy burden of disease and economic burden but have fewer treatment options. Sorafenib, a multi-kinase inhibitor, is the only approved drug that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results